Mittelman Wealth Management Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Mittelman Wealth Management acquired a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,015 shares of the medical equipment provider's stock, valued at approximately $1,515,000. Hologic makes up approximately 1.4% of Mittelman Wealth Management's investment portfolio, making the stock its 12th largest holding.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Hologic by 4.1% in the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock worth $343,000 after acquiring an additional 188 shares during the period. Capital Investment Counsel Inc grew its position in shares of Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock worth $413,000 after purchasing an additional 200 shares in the last quarter. Dark Forest Capital Management LP raised its stake in Hologic by 7.9% during the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock valued at $220,000 after purchasing an additional 223 shares during the period. Finally, Baker Avenue Asset Management LP lifted its holdings in Hologic by 0.5% in the 4th quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after purchasing an additional 225 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Royal Bank of Canada cut their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Morgan Stanley cut their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Evercore ISI cut their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Hologic has a consensus rating of "Hold" and a consensus target price of $77.42.

Insider Activity

In related news, Director Martin D. Madaus acquired 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now directly owns 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.88% of the company's stock.

Hologic Trading Up 2.9%

Shares of NASDAQ:HOLX traded up $1.78 during trading hours on Wednesday, hitting $63.95. 4,059,342 shares of the company's stock traded hands, compared to its average volume of 2,222,311. The firm has a market capitalization of $14.25 billion, a P/E ratio of 20.22, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The business has a fifty day moving average price of $58.05 and a 200-day moving average price of $66.23. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the company earned $1.03 EPS. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. Equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.